Publications

Kim S, Thompson CM, Kopec AK, Harris MA, Zacharewski TR. Comparison of basal and CrVI-mediated solute carrier gene expression in rodent duodenal epithelium. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Thompson CM, Grafström RC. 2011. Considerations for the implausibility of leukemia induction by formaldehyde. Toxicol Sci 120(1):230-232; doi: 10.1093/toxsci/kfq340. PMID: 21059796.

Thompson CM, Haws LC, Harris MA, Gatto NM, Proctor DM. 2011. Application of the U.S. EPA mode of action framework for purposes of guiding future research: A case study involving the oral carcinogenicity of hexavalent chromium. Toxicol Sci 119(1):20-40; doi: 10.1093/toxsci/kfq320. PMID: 20947717.

Johns DO, Owens EO, Thompson CM, Sonawane B, Hattis D, Krishnan K. 2010. Physiological parameters and databases for PBPK modeling. Chapter 5 in: Quantitative Modeling in Toxicology. Krishnan K, Andersen M (eds.). Wiley, p. 107.

Thompson CM, Ceder R, Grafström RC. 2010. Formaldehyde dehydrogenase: Beyond phase I metabolism. Toxicol Lett 193(1):1-3; doi: 10.1016/j.toxlet.2009.11.023. PMID: 19963048.

Thompson CM, Grafstrom RC. 2009. Commentary: Mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma. Environ Health 8:53; doi: 10.1186/1476-069X-8-53. PMID: 19939253.

Thompson CM, Sonawane B, Grafström RC. 2009. The ontogeny, distribution and regulation of alcohol dehydrogenase 3: Implications for pulmonary physiology. Drug Metab Disposit 37(8):1565-1571; doi: 10.1124/dmd.109.027904. PMID: 19460944.

Thompson CM, Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060. PMID: 19117207.

Makris SL, Thompson CM, Euling SY, Selevan SG, Sonawane B. 2008. A lifestage-specific approach to hazard and dose-response characterization for children’s health risk assessment. Birth Defects Res B 83(6):530–546; doi: 10.1002/bdrb.20176. PMID: 19085945.

Thompson CM, Subramaniam RP, Grafström RC. 2008. Mechanistic and dose considerations for supporting adverse pulmonary physiology in response to formaldehyde. Toxicol Appl Pharmacol 233(3):355–359; doi: 10.1016/j.taap.2008.09.011. PMID: 18851987.

Subramaniam RP, Chen C, Crump KS, Devoney D, Fox JF, Portier CJ, Schlosser PM, Thompson CM, White P. 2008. Uncertainties in biologically-based modeling of formaldehyde-induced respiratory cancer risk: Identification of key issues. Risk Anal 28(4):907–923; doi: 10.1111/j.1539-6924.2008.01083.x. PMID: 18564991.

Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B 11(7):519–547; doi: 10.1080/10937400701724337. PMID: 18584453.

DeWoskin RS, Thompson CM. 2008. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol 51(June):66–86; doi: 10.1016/j.yrtph.2008.02.005. PMID: 18433959.

Thompson CM, Grafström RC. 2007. Mechanistic considerations for formaldehyde-induced bronchoconstriction involving S-nitrosoglutathione reductase. J Toxicol Environ Health A 71(3):244–248; doi: 10.1080/15287390701598259; PMID: 18097950.

Barone S Jr., Brown RC, Euling S, Cohen Hubal E, Kimmel CA, Makris S, Moya J, Selevan SG, Sonawane B, Thomas T,  Thompson CM. 2006. Visión general de la evaluación del rieso en salud infantil empleando un enfoque por etapas de desarrollo. Acta Toxicol Argent 14(Suppl):7–10.

Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE. 2004. Activation of G-proteins by morphine and codeine congeners: Insights to the relevance of O- and N-demethylated metabolites at μ- and δ-opioid receptors. J Pharmacol Exper Therapeut 308(2):547–554; doi: 10.1124/jpet.103.058602. PMID: 14600248.

Strobel HW, Thompson CM, Antonovic L. 2001. Cytochromes P450 in brain: Function and significance. Curr Drug Metabol 2(2):199–214; doi: 10.2174/1389200013338577. PMID: 11469726.

Thompson CM, Capdevila JH, Strobel HW. 2000. Recombinant P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exper Ther 294(3):1120–1130; doi: 10.1016/S0022-3565(24)39180-3. PMID: 10945868.

Thompson CM, Kawashima H, Strobel HW. 1998. Isolation of partially purified P450 2D18 and characterization of activity towards the tricyclic antidepressants imipramine and desipramine. Arch Biochem Biophys 359(1):115–121; doi: 10.1006/abbi.1998.0892. PMID: 9799568.